A carregar...
Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maintenance Therapy
Bortezomib is the first therapeutic inhibitor of the proteasome that has demonstrated a significant clinical response in patients with otherwise refractory or rapidly advancing disease. Bortezomib has received US Federal Drug Administration approval for the treatment of the hematologic malignancies...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3448445/ https://ncbi.nlm.nih.gov/pubmed/21248621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MJT.0b013e3181ff7a9e |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|